The Fe 3 O 4 /reduced graphene oxide (Fe 3 O 4 /RGO) nanocomposites with good dispersibility were synthesized for targeted delivery of paclitaxel (PTX). Firstly, the superparamagnetic Fe 3 O 4 /functional GO nanocomposites were prepared via hydrothermal method in which GO sheets were modified by surfactant wrapping. The Fe 3 O 4 /RGO nanocomposites were successively prepared through the reduction of graphene oxide. The products were investigated by Fourier-transform infrared spectrum, X-ray diffraction, scanning electron microscopy, transmission electron microscopy, thermogravimetric analysis, and vibration sample magnetometry. It was found that spherical Fe 3 O 4 nanoparticles were uniformly anchored over the RGO matrix and the nanocomposites were superparamagnetic with saturation magnetization (Ms) of 9.39 emu/g. Then PTX was loaded onto Fe 3 O 4 /RGO nanocomposites, and the drug loading capacity was 67.9%. Cell viability experiments performed on MCF-7 demonstrated that the Fe 3 O 4 /RGOloaded PTX (Fe 3 O 4 /RGO/PTX) showed cytotoxicity to MCF-7, whereas the Fe 3 O 4 /RGO displayed no obvious cytotoxicity. The above results indicated that Fe 3 O 4 /RGO/PTX nanocomposites had potential application in tumor-targeted chemotherapy.
Introduction
Paclitaxel (PTX) is used for the first-line chemotherapeutics in breast cancer, lung cancer, and so on [1] . For improving the bioavailability of PTX, some groups made different carriers to load PTX such as hydrogels [2, 3] , gel system [4] , implantable chitosan film [5] , nanogel [6] , nanoparticles [7, 8] , and nanostructured lipid carrier [9] .
The graphene nanocomposites were studied for drug loading and delivery, since the hydrophobic drugs can be loaded on to graphene sheets by -stacking. For example, Angelopoulou et al. developed GO/PLA-PEG nanocomposites loading with PTX, which showed satisfactory high loading capacity, controlled release, and cytoxicity against A549 cancer cells [10] . Zhang et al. synthesized PEG modified nano graphene oxide for delivering PTX and indocyanine green (ICG), which had good fluorescence labeling and therapy effect [11] .
Moreover, graphene is used as nanoscale building blocks for new nanocomposites because of its unique properties [12] [13] [14] . Recent research showed that magnetic nanoparticles (MNPs) could be attached to graphene, which can be applied in magnetic resonance imaging [15] , targeted drug delivery [16, 17] , biocompatible adsorbent [18] , magnetic solid phase extraction [19] , microwave electromagnetic [20] , Schottky diode applications [21] , and biomolecule immobilization [22] . Thus, the bifunctional graphene drug delivery system for magnetic targeting and drug loading was developed in this paper.
In this paper, the magnetic graphene oxide (Fe 3 O 4 /GO) for delivering PTX was prepared by hydrothermal method, and Fe 3 O 4 /GO was subsequently reduced to Fe 3 O 4 /RGO with good dispersibility. The Fe 3 O 4 /RGO nanocomposites were characterized, and the drug loading and release of PTX were also investigated. Furthermore, the inhibitory effect of Fe 3 O 4 /RGO-loaded PTX (Fe 3 O 4 /RGO/PTX) on MCF-7 cells was conducted. ⊖  ＆？  3+ ＆？  3+ ＆？  3+ ＆？  3+ ＆？  3+ ＆？   3+   ＆？   3+   ＆？   3+   ＆？   3+   ＆？   3+   ＆？   3+   ＆？   3+   ＆？   3+   ＆？   3+   ＆？ Poly(sodium 4-styrenesulfonate) (PSS) were of analytical grade. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), PTX, and Triblock copolymers (PEO 99 -PPO 67 -PEO 99 ) PF127 were purchased from Sigma. The graphene oxide (GO) was purchased by Xian'feng Nanotechnologies Co. Ltd., China. 3 O 4 /RGO/PTX Nanocomposites. To control the particle size of Fe 3 O 4 nanoparticles, the GO was modified by the polymer wrapping technique, in which cationic CTAB (1 g) was adsorbed firstly on GO to create a charged template and anionic PSS (0.24 g) was subsequently grafted onto the surfaces of GO (as shown in Figure 1 ). The mixture of GO modified by CTAB and PSS was obtained, named functional GO (f-GO). The assembly of Fe 3 O 4 nanoparticles on f-GO (Fe 3 O 4 /f-GO) was self-prepared using hydrothermal reaction [23] . For comparison, we synthesized Fe 3 O 4 /GO without modifying GO.
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Synthesis and Application of Fe

Synthesis of Fe
Secondly, PF127 (400 mg) was dropped to Fe 3 O 4 /f-GO solution (15 mL, 1.0 mg/mL) and hydrazine monohydrate (400 L) was then added to reduce the GO [24] . After reaction, Fe 3 O 4 /RGO nanocomposites were obtained by pressure filtration. Lastly, the PTX was loaded by adding 0.01 g Fe 3 O 4 /RGO to PBS buffer solution containing PTX (1 mg/mL, 30 mL) at 25 ∘ C for 16 h in dark. The suspension was centrifuged and freeze-dried, and Fe 3 O 4 /RGO/PTX was obtained. 
Drug Release of Fe
Characterization.
The structure was characterized by Xray diffraction (Bruker D8, XRD). Bruker VECTOR 22 spectrometer was used to measure infrared spectrum (IR). The morphology was measured by scanning electron microscopy (Model S-4800, SEM) and transmission electron microscopy (Tecnai 12, TEM). Thermogravimetric analysis was characterized by thermal analyzer (TA2100, America TA). And vibration sample magnetometry (Lake Shore 7410, VSM) was used to detect the magnetic properties. Figure 2 , the diffraction peak of f-GO appeared at 22.9
Results and Discussion
XRD Analysis. As exhibited in
∘ which originated from the Journal of Nanomaterials diffraction on its (002) layer planes [26] . The reflection peaks at 30.1 ∘ , 35.4 ∘ , 43.1 ∘ , 53.5 ∘ , 56.9 ∘ , and 62.5 ∘ can be assigned to (220), (311), (400), (422), (511), and (440) crystal planes of cubic magnetite [27] . It can be concluded that the magnetite-GO heterostructure was formed. was assigned to -OH bond, and the C=C bond was exhibited at 1617 cm −1 . In Figure 3(b) , the Fe-O [28, 29] characteristic band appeared at 700 cm −1 . In addition, the bands at 2975 cm −1 and 2890 cm −1 (Figure 3(c) ) could be ascribed to -CH 3 and -CH 2 , which exhibited that Fe 3 O 4 /RGO was successfully modified by PF127. In Figure 3(d) , the peaks at 1072, 1247, 707, 1652, and 1722 cm −1 could be ascribed to the C-O ester, -COO, C-H aromatic, C=O amide, and C=O ester [30] . It can be concluded that PTX was loaded on Fe 3 O 4 /RGO/PTX. Figure 4 (a) showed that the GO had flake structure. After surfactant modification, the f-GO (Figure 4(b) ) had good dispersibility. From Figure 4 (c), before GO modification, few Fe 3 O 4 nanoparticles were supported on the GO nanosheets. After GO modification, Figure 4 (d) exhibited that spherical Fe 3 O 4 nanoparticles were homogeneously distributed over the GO nanosheets, because the modified GO were covered with a negatively charged polyelectrolyte which can insure homogenous, highdensity coverage of positively charged Fe 3+ by electrostatic attraction. In Figure 4 (e), after PF127 modification and reduction, Fe 3 O 4 nanoparticles of 100 nm were loaded on the surface of RGO nanosheets. In addition, no free Fe 3 O 4 nanoparticles were observed outside of RGO, indicating a strong interaction between Fe 3 O 4 nanoparticles and RGO by modification by PF127. In Figure 4 (f), it was observed that the Fe 3 O 4 /RGO/PTX had good morphology and dispersability, which could be applied in subsequent experiments. Figure 5(a) showed TEM images of f-GO, which exhibited a typical wrinkled morphology and good dispersibility. In Figure 5 (b), it was found that the GO carbon sheets were decorated by Fe 3 O 4 nanoparticles with diameters from 50 nm to 100 nm. From the TEM of Fe 3 O 4 /f-GO nanocomposites with high resolution (Figure 5(c) ), it was exhibited that Fe 3 O 4 nanoparticles supported on GO nanosheets had good dispersibility and sphericity. After being modified by PF127 ( Figure 5(c) ), the Fe 3 O 4 /RGO nanocomposites had good dispersibility, from which it can be concluded that good dispersibility may be ascribed to the PF127 immobilization. After loading with PTX ( Figure 5(d) ), Fe 3 O 4 nanoparticles were still firmly anchored on the surface of RGO. Figure 6 (a), 40.4% mass loss before 200 ∘ C was due to desorption of H 2 O and pyrolysis of oxygen-containing group [24] . The pyrolysis of carbon skeleton was exhibited at 50.3% mass loss between 200 and 550 ∘ C. Figure 6 (b) showed that 17.4% weight loss before 300 ∘ C was the removal of labile groups. A further 32.2% weight loss at 400 ∘ C (Figure 6(b) ) was due to the decomposition of carboxyl group. From Figure 6 (c), 3.6% weight loss below 200 ∘ C was corresponding to labile oxygen-containing functional groups. A further 32.3% weight loss was observed at around 400 ∘ C (Figure 6(c) ), which was due to the decomposition of PF127. Finally, 43.1% at around 500 ∘ C was ascribed to the carbon skeleton pyrolysis. Figure 7 (a), the products showed superparamagnetism without any hysteresis [31] . The saturation magnetization ( ) of Fe 3 O 4 /f-GO was 9.39 emu/g. Before GO modification, the of as-obtained Fe 3 O 4 /GO nanocomposites decrease to 6.50 emu/g; it was due to the fewer Fe 3 O 4 nanoparticles supported on the GO nanosheets. After drug loading, the of Fe 3 O 4 /RGO/PTX was 5.23 emu/g (Figure 7(c) ). It could be seen that Fe 3 O 4 /RGO/PTX maintained good saturation magnetization, which was critical for further application. In Figure 8 , a sustained PTX release at different pH values was observed from the Fe 3 O 4 /RGO/PTX. About 96.6% (Figure 8(a) ) and 52.1% (Figure 8(b) ) of PTX were released at pH = 5.5 and pH = 7.4 after 120 h. Moreover, the decreasingstacking was the reason for rapid PTX release at pH = 5.5.
FT-IR
SEM Analysis.
TEM Analysis.
TG Analysis. From
VSM Analysis. In
In Vitro Cytotoxicity
Assay. In Figure 9 (a), the free Fe 3 O 4 /RGO had no considerable cytotoxicity to MCF-7 cells. In Figure 9 (b), with adding the Fe 3 O 4 /RGO/PTX, an obvious decrease in cell viability was observed. When the concentration of Fe 3 O 4 /RGO/PTX was 200 g/mL, the cell viability was reduced to 31%. With adding the 500 g/mL Fe 3 O 4 /RGO/PTX, the cell viability was rapidly reduced to 11%. It can be concluded that with increasing Fe 3 O 4 /RGO/PTX concentration the cell viability of MCF-7 decreased.
The cell viability results of products were also confirmed by fluorescence microscopy. The largest number of viable cells was exhibited in the control group (Figure 10(a) ). With adding Fe 3 O 4 /RGO with different concentration (Figure 10(b) , 1 g/mL; Figure 10 (c), 10 g/mL; and Figure 10(d) , 100 g/mL), MCF-7 cells had no obvious morphological change.
The maximum viable cells were shown in the control group (Figure 11(a) ). In Figure 11 (b), with adding 100 g/mL of Fe 3 O 4 /RGO/PTX, the number of viable MCF-7 cells reduced rapidly. When the concentration of PF127/ Fe 3 O 4 /RGO/PTX increased to 200 and 500 g/mL, few cells were observed (Figures 11(c) and 11(d) ). It was confirmed that Fe 3 O 4 /RGO/PTX showed high antitumor activity for MCF-7 cells, which was ideal materials for tumor-targeted chemotherapy. 
Conclusions
In conclusion, 
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